Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Franklin BSP Realty Trust (FBRT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities between November 5, 2024 and February 11, 2026 in Franklin BSP Realty Trust and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 26, 2026 ...

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Canada Goose Holdings Inc. for possible violations of federal securities laws and unlawful business practices [1][2] Group 1: Company Performance - On February 5, 2026, Canada Goose reported its third quarter fiscal 2026 results, indicating that margins reflected deliberate choices to expand product relevance and fuel brand momentum [2] - Following the announcement, Canada Goose's share price fell by $2.57, approximately 19.4%, from $13.22 on February 4, 2026, to close at $10.65 on February 5, 2026 [2] Group 2: Legal Actions - Investors who purchased or acquired Canada Goose shares and suffered losses are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights [1][3] - The law firm offers no cost or obligation for investors seeking to learn more about potential claims [3] Group 3: Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and consumer protection [4]

LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION [Accessibility Statement] Skip NavigationShareholders Who Purchased INO Securities During Class Period Urged to Review OptionsNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO).YOU MAY BE AFFECTED IF YOU:- Acquired shares during the Class Period- Lost money on your Inovio inves ...

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged misleading statements and failure to disclose critical information regarding its CELLECTRA device and the INO-3107 Biologics License Application [2][5]. Allegation Details - The lawsuit claims that during the Class Period, Inovio made false statements about the manufacturing quality of its CELLECTRA device, which impacted the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024 [5]. - It is alleged that Inovio lacked sufficient information to support the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered financial damages, particularly after the FDA's announcement regarding the BLA's acceptance on a standard review timeline rather than accelerated approval [5]. Stock Price Impact - Following the FDA's announcement on December 29, 2025, Inovio's stock price dropped by $0.56 per share, representing a decline of 24.45%, closing at $1.73 per share [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Agilon (AGL) To Contact Him Directly To Discuss Their Options If you purchased or acquired Agilon securities between February 26, 2025 and August 4, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- What’s Happening? Brag ...

New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Alight, Inc. ("Alight, Inc.") (NYSE: ALIT) concerning potential violations of the federal securities laws.Alight's Q4 2025 results landed below the low end of the Company's own full-year 2025 guidance range. On the Q3 2025 earnings call on November 5, 2025, CFO Jeremy Heaton told investors the Company expected full-year 2025 EPS of $0.54 to $0.58 and revenue between $2. ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Kyndryl Holdings, Inc. (NYSE: KD)  (“Kyndryl” or the “Company”) inclusive on behalf of all persons and entities that purchased or otherwise acquired Kyndryl shares August 7, 2024 and February 9, 2026, both dates inclusive (the "Class Period"). Investors have until April 13, 2026, to seek appointments as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMI ...

Core Viewpoint - ICON Public Limited Company is under investigation for potential violations of federal securities laws following a significant decline in shareholder value due to a revenue overstatement disclosure and a delay in earnings release [1][2][3]. Financial Performance and Market Reaction - The company's single-day stock decline resulted in the loss of billions of dollars in shareholder value, marking one of the largest percentage drops in the Contract Research Organization (CRO) sector in recent years [2]. - Prior to the disclosure, ICON's stock reflected investor confidence, with a consensus revenue range of $8.05 billion to $8.1 billion and adjusted EPS guidance of $13.00 to $13.20 for full-year 2025 [2]. - The abrupt sell-off indicated that the market had not anticipated risks related to revenue overstatement or delays in earnings release [2]. Revenue Overstatement and Earnings Delay - ICON disclosed a preliminary revenue overstatement of under two percent per year for fiscal years 2023 and 2024, along with a delay in releasing Q4 and full-year 2025 results [3]. - CEO Barry Balfe had previously assured investors that the company's performance was "broadly in line with expectations" [3]. - CFO Nigel Clerkin reported Q3 2025 revenue of $2.043 billion, reflecting a year-over-year increase of 0.6 percent, based on figures now under scrutiny [3]. Stock Buyback and Future Guidance - In the quarters leading up to the disclosure, ICON repurchased $750 million of its own stock and had a new $1 billion buyback authorization, indicating confidence in its financial position [4]. - A filing on January 7, 2026, indicated that full-year 2026 guidance would be released alongside the delayed Q4 and full-year 2025 results, which is now uncertain due to the delay [4].

Core Insights - Hub Group, Inc. is under investigation for potential violations of federal securities laws following a significant accounting error that has impacted investor confidence and stock performance [1][3]. Stock Performance - Hub Group's stock reached a 52-week high of $48.96 on February 3, 2026, but plummeted to around $37 just three days later, resulting in a loss of approximately $12 per share [2]. - For an investor holding 10,000 shares, this decline translates to an estimated $120,000 decrease in portfolio value [2]. Analyst Reactions - Stifel downgraded Hub Group from a Buy rating to Sell, slashing its price target from $52 to $27, a 48% reduction [3]. - Baird also downgraded its rating from Outperform to Neutral, reducing its target from $47 to $29, a 38% cut [3]. - Both downgrades were issued on February 6, contributing to increased selling pressure on the stock [3]. Financial Results - Despite reporting earnings per share of $0.45 against a consensus estimate of $0.44 and revenue exceeding estimates, the positive results were overshadowed by the disclosure of an accounting restatement affecting three prior quarters and an estimated $77 million in understated costs [4]. - The market's reaction, with a 23% decline in stock price, indicates that the accounting issue is viewed as more significant than the quarterly earnings performance [4].

Core Viewpoint - Kyndryl Holdings, Inc. is facing significant scrutiny due to internal control weaknesses and cash management practices, leading to a substantial decline in stock price and potential legal claims from investors [4][5][6]. Group 1: Company Disclosures - On February 9, 2026, Kyndryl disclosed that its Audit Committee is reviewing cash management practices and related disclosures following voluntary document requests from the SEC's Division of Enforcement [4]. - Kyndryl expects to report material weaknesses in internal control over financial reporting for multiple reporting periods, indicating that previous assessments and auditor opinions should no longer be relied upon [5]. - The company announced the immediate departures of its Chief Financial Officer and General Counsel, and it will delay the filing of its Quarterly Report on Form 10-Q [6]. Group 2: Market Impact - Following the disclosures regarding internal control issues and management changes, Kyndryl's stock price declined approximately 50% on February 9, 2026 [6]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is investigating potential claims against Kyndryl for investors who suffered significant losses, encouraging affected investors to discuss their legal rights [2][3].